Zobrazeno 1 - 10
of 11
pro vyhledávání: '"W Larry Gluck"'
Autor:
Jonah Shealy, Alex Kesic, Avery Funkhouser, Julie Martin, W. Larry Gluck, w. Jeffery Edenfield, Anna Blenda
Publikováno v:
Cancer Research. 83:P2-23
Background: Galectins are sugar binding proteins that play a role in adhesion, apoptosis, immune regulation, and many other cellular processes. There are three different classes of galectins, and they are all found intracellularly and secreted in ser
Autor:
Alex Kesic, Avery Funkhouser, Jonah Shealy, Julie Martin, W. Larry Gluck, William J. Edenfield, Anna Blenda
Publikováno v:
Cancer Research. 83:P2-26
Glycobiology has proved to be a new frontier in oncology research in recent years. One sector of glycobiology involves examining glycan expression of cancerous cells. Glycans are complex carbohydrates found on cell surfaces, and patterns of aberrant
Autor:
Robert A. Brevetta, Sergio Arce, Antine E. Stenbit, Julie C. Martin, Wesley M. Smith, W Larry Gluck, W Jeffery Edenfield, Sean P. Callahan, Anna V. Blenda
Publikováno v:
Journal of Cellular Immunology. 3
Publikováno v:
Colorectal Cancer. 6:57-61
Emerging evidence suggests a small subset of late-stage colon cancer driven by HER2, a biomarker routinely evaluated in select breast and gastric cancers, may respond to HER2-targeted therapy. Herein, we describe a 49-year-old male with widely metast
Autor:
Julie C. Martin, Robert A. Brevetta, Sean P. Callahan, Wesley M. Smith, W Larry Gluck, W Jeffery Edenfield, Antine E. Stenbit, Anna V. Blenda, Sergio Arce
Publikováno v:
Respiratory Medicine
Objectives Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improvin
Autor:
Jean-Yves Blay, Andrew J. Wagner, Mrinal M. Gounder, David S. Siegel, H. Henary, Erik Rasmussen, Richard Frank, W. Larry Gluck, Sant P. Chawla, Ferry A.L.M. Eskens, Philippe A. Cassier, Filip de Vos, Vincent A. de Weger, Jean-Charles Soria
Publikováno v:
Investigational New Drugs
Investigational New Drugs, 38(3), 831-843. Kluwer Academic
Investigational New Drugs, 38(3), 831. Kluwer Academic Publishers
Investigational New Drugs, 38(3), 831-843. Kluwer Academic
Investigational New Drugs, 38(3), 831. Kluwer Academic Publishers
SummaryBackground This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), pat
Autor:
Wendy Burke, Stephen Green, Manish Patel, Patricia LoRusso, Elisabeth Oelmann, Erika Hamilton, Muaiad Kittaneh, Donald K Strickland, Howard A. Burris, Suzanne F. Jones, W Larry Gluck
Publikováno v:
Cancer Research. 75:P6-12
Background: Preclinical data suggest that patients with ER+ Breast Cancer become less sensitive to hormonal therapy by upregulation of the mTOR pathway. BOLERO-2 demonstrated that the combination of an allosteric mTOR inhibitor and an aromatase inhib
Publikováno v:
Journal of Clinical Oncology. 34:TPS778-TPS778
TPS778 Background: Phosphorylated p68 may play a vital role in cell proliferation and tumor/cancer progression. RX-5902 is a novel compound that targets phosphorylated p68 RNA helicase (also known as DDX5), a member of the DEAD box family of RNA heli
Autor:
W Larry Gluck, Erika Hamilton, Muaiad Kittaneh, Sabina Cosulich, Wendy Burke, Suzanne F. Jones, Patricia LoRusso, Stephen Green, Manish Patel, Donald K Strickland, Elisabeth Oelmann, Elizabeth A. Harrington, Howard A. Burris
Publikováno v:
Cancer Research. 75:CT233-CT233
Background: Preclinical and clinical (BOLERO 2) data suggest that pts with ER+ breast cancer become less sensitive to hormonal therapy over time with greater dependency on the mTOR pathway. AZD2014 is a selective dual mTORC1 and mTORC2 inhibitor that
Autor:
Robert M. Jotte, Lei Zhou, Lowell L. Hart, Alain C. Mita, Dawn Hill, Anne C. Chiang, David R. Spigel, W Larry Gluck, Jakob Dupont, Ann M. Kapoun, Shirish M. Gadgeel, Lu Xu, Stephen V. Liu, Maria Catherine Pietanza, Alexander I. Spira
Publikováno v:
Journal of Clinical Oncology. 33:7508-7508
7508 Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation; thus being an appealing target in the treatment of SCLC. Tarextumab (TRXT), a fully human IgG2 ant...